Clover Health Investments Corp (CLOV) concluded trading on Wednesday at a closing price of $4.31, with 7.54 million shares of worth about $32.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 156.55% during that period and on January 22, 2025 the price saw a gain of about 1.65%. Currently the company’s common shares owned by public are about 394.44M shares, out of which, 376.30M shares are available for trading.
Stock saw a price change of 15.24% in past 5 days and over the past one month there was a price change of 36.83%. Year-to-date (YTD), CLOV shares are showing a performance of 36.83% which increased to 359.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.61 but also hit the highest price of $4.71 during that period. The average intraday trading volume for Clover Health Investments Corp shares is 6.02 million. The stock is currently trading 20.69% above its 20-day simple moving average (SMA20), while that difference is up 26.67% for SMA50 and it goes to 80.51% higher than SMA200.
Clover Health Investments Corp (NASDAQ: CLOV) currently have 394.44M outstanding shares and institutions hold larger chunk of about 16.40% of that.
The stock has a current market capitalization of $2.16B and its 3Y-monthly beta is at 2.00. It has posted earnings per share of -$0.19 in the same period. It has a debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLOV, volatility over the week remained 5.59% while standing at 5.76% over the month.
Analysts are in expectations that Clover Health Investments Corp (CLOV) stock would likely to be making an EPS of -0.06 in the current quarter, while forecast for next quarter EPS is -0.04 and it is -0.1 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.07 which is -0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.11 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 73.20% while it is estimated to decrease by -16.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on December 17, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by UBS stated Clover Health Investments Corp (CLOV) stock as a Neutral in their note to investors on October 07, 2024, suggesting a price target of $4 for the stock. On February 02, 2022, Cowen Upgrade their recommendations, while on February 02, 2022, Canaccord Genuity Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on January 19, 2022.
